What is the purpose of this study?

The DNA repair capacity (DRC) is a measure of a cell’s ability to repair DNA damage. High levels of DNA damage are observed in many lung diseases, including lung cancer and chronic obstructive lung disease (COPD, sometimes referred to as emphysema or chronic bronchitis). We believe that patients with a lower DRC may be at higher risk for development of lung diseases including lung cancer and COPD. The purpose of this study is to measure the DRC in peripheral blood monocytes from smoking and non-smoking patients with and without lung cancer compared to healthy controls

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. 

Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:

IU Clinical Trials Office 

Email: iutrials@iu.edu 

Phone: (317) 278-5632

You may be eligible for this study if you meet the following criteria:

• Conditions: Lung Cancer, Healthy
• Age: 18 years - 100 years
• Gender: All